The drug iscentrally penetrant and is devoid ofantagonism of the vasopressinV2 andoxytocin receptors.[5] Clinical studies found induction of subtle improvements but also subtle deficits in social communication surrogates with RG7713 in adult men with high-functioning autism.[5][4] A 2024meta-analysis of vasopressin V1A receptor antagonists including RG7713 for autism found that they may not be effective in the treatment of the core symptoms of autism.[6]
As of December 2018, no recent development has been reported.[2] It reachedphase 1clinical trials.[2]Balovaptan (RG7314) has been described as a follow-up compound of RG7713 and reached later-stage clinical trials but was found to be ineffective.[3][6][7]
^abcde"RG 7713".AdisInsight. 28 December 2018. Retrieved27 October 2024.
^abChadman KK, Fernandes S, DiLiberto E, Feingold R (August 2019). "Do animal models hold value in Autism spectrum disorder (ASD) drug discovery?".Expert Opinion on Drug Discovery.14 (8):727–734.doi:10.1080/17460441.2019.1621285.PMID31132011.
^abHong MP, Erickson CA (August 2019). "Investigational drugs in early-stage clinical trials for autism spectrum disorder".Expert Opinion on Investigational Drugs.28 (8):709–718.doi:10.1080/13543784.2019.1649656.PMID31352835.
^abLacivita E, Perrone R, Margari L, Leopoldo M (November 2017). "Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions".Journal of Medicinal Chemistry.60 (22):9114–9141.doi:10.1021/acs.jmedchem.7b00965.PMID29039668.
^abKimi S, Maiti R, Srinivasan A, Mishra BR, Hota D (February 2024). "Efficacy and safety of V1a receptor antagonists in autism spectrum disorder: A meta-analysis".International Journal of Developmental Neuroscience.84 (1):3–13.doi:10.1002/jdn.10297.PMID37641183.
^Jacob S, Veenstra-VanderWeele J, Murphy D, McCracken J, Smith J, Sanders K, et al. (March 2022). "Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial".The Lancet. Psychiatry.9 (3):199–210.doi:10.1016/S2215-0366(21)00429-6.PMID35151410.
